Alnylam Pharmaceuticals
ALNY
821 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 282 increasing their positions, 223 reducing their positions, and 49 closing their positions.
357% more first-time investments, than exits
New positions opened: 224 | Existing positions closed: 49
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
37% more capital invested
Capital invested by funds: $43.1B → $59.2B (+$16.1B)
26% more repeat investments, than reductions
Existing positions increased: 282 | Existing positions reduced: 223
26% more funds holding
Funds holding: 653 → 821 (+168)
2.24% less ownership
Funds ownership: 101.33% → 99.09% (-2.2%)
13% less call options, than puts
Call options by funds: $562M | Put options by funds: $649M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.01B |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$483M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$391M |
| 4 |
Jane Street
New York
|
+$381M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$330M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RP
Regeneron Pharmaceuticals
Tarrytown,
New York
|
-$1.24B |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$858M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$548M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$479M |
| 5 |
Dodge & Cox
San Francisco,
California
|
-$357M |
ALNY Hedge Fund Activity: Q3 2025 in Review
821 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2025, worth a combined $59.2B — up 37% from $43.1B a quarter earlier.
Buyers outnumbered sellers: 224 funds opened new ALNY positions and 49 closed out — a net gain of 175 holders — while 282 added to existing stakes and 223 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $1.01B. The largest seller was Regeneron Pharmaceuticals, cutting an estimated $1.24B.
- 821 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2025, up from 653 in Q2 2025.
- Funds reported $59.2B of Alnylam Pharmaceuticals stock for Q3 2025, up 37% quarter-over-quarter.
- 224 funds opened new Alnylam Pharmaceuticals positions in Q3 2025 and 49 closed out, a net change of +175 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2025 was JP Morgan Chase, an estimated $1.01B added.
- The largest Alnylam Pharmaceuticals seller in Q3 2025 was Regeneron Pharmaceuticals, an estimated $1.24B sold.
Based on aggregated 13F filings for Q3 2025.